Nasdaq ardx.
Nov 16, 2023 · Ardelyx Inc (NASDAQ:ARDX) showed a performance of -1.41% in past 30-days. Number of shares sold short was 36.47 million shares which calculate 4.09 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $9.64 to the stock, which implies a rise of 59.96% to its recent value today. Jul 18, 2021 · Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ... After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of …Ardelyx Stock (NASDAQ:ARDX), Short Interest Report. Short interest for Ardelyx gives investors a sense of the degree to which investors are betting on the decline of Ardelyx's stock.
Ardelyx, Inc. (NASDAQ:ARDX) has gained about 353% over the past 12 months. As of the end of the first quarter of 2023, 20 hedge funds tracked by Insider Monkey were long Ardelyx, Inc. (NASDAQ:ARDX ...Complete Ardelyx Inc. stock information by Barron's. View real-time ARDX stock price and news, along with industry-best analysis. WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Ardelyx Inc (NASDAQ:ARDX) 4.34 Delayed Data As of Nov 17 +0.305 / +7.57% Today’s Change 1.56 Today ||| 52-Week Range 5.13 +52.11% Year-to-Date Quote Profile News …
The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ... The put contract at the $4.00 strike price has a current bid of 15 cents. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $4.00, but will also ... Ardelyx Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ARDX updated stock price target summary.A high-level overview of Ardelyx, Inc. (ARDX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Principal Financial Group Inc. acquired a new stake in shares of Ardelyx, Inc. (NASDAQ:ARDX – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 24,269 shares of the biopharmaceutical company’s stock, valued at approximately $82,000. …
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2023 Earnings Call Transcript (Insider Monkey) Oct-31-23 11:15PM Q3 2023 Ardelyx Inc Earnings Call (Thomson Reuters StreetEvents) +9.12%. 05:09PM Why Ardelyx Stock Soared Today (Motley Fool) 08:40AM Ardelyx (ARDX) Q3 Earnings and Revenues Top Estimates ...
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in ...730% upside stock according to Citigroup Ardelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the …Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Health care stocks were finishing near their Friday highs this afternoon, with the NYSE Health Care Index rising 1.0% while the Health Care Select Sector SPDR Fund (XLV) was up 0.9%.Get Ardelyx Inc. (ARDX) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, financial report, etc.Ardelyx Inc (NASDAQ: ARDX) Ardelyx is a biotech penny stock which already has a successful product on the market . Ibsrela (tenapanor) is a drug that was introduced by the company in March 2022. It is used …
ARDELYX INC ( ARDX) is a small-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 100% based on the firm’s underlying fundamentals and the stock’s ...Find the latest press releases from Ardelyx, Inc. Common Stock (ARDX) at Nasdaq.com.Analysts' Revenue Estimates For Ardelyx, Inc. (NASDAQ:ARDX) Are Surging Higher Dec 02. Ardelyx Announces Launching of IBSRELA® Second Quarter of 2022 Dec 01. Insider notifies of intention to sell stock Nov 19. Third quarter 2021 earnings released: US$0.42 loss per share (vs US$0.20 loss in 3Q 2020)Based on analysts offering 12 month price targets for ARDX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Ardelyx (NASDAQ:ARDX) is another hot penny stock to consider. The biotech stock, which has a market cap of $550 million and is trading at $2.94, could see higher highs.
Ardelyx Inc. (NASDAQ:ARDX) is a biopharmaceutical company based in Waltham, Massachusetts. The company develops and commercialized medicines to treat gastrointestinal and cardiorenal therapeutic ...Ardelyx (NASDAQ: ARDX). $4.37. (6.8%). $0.28. Price as of November 29, 2023, 4:00 p.m. ET. Jump to: Overview. OverviewReturn vs. S&PCompany InfoNews & Analysis ...
Ardelyx (NASDAQ:ARDX) is a biotechnology company that focuses on developing novel therapies for unmet medical needs. The company’s growth and potential breakthroughs in medical treatments could ...Ulysses Erickson. November 20, 2023. In the latest trading session, 1.04 million Ardelyx Inc (NASDAQ:ARDX) shares changed hands as the company’s beta touched 1.03. With the company’s most recent per share price at $4.30 changed hands at -$0.03 or -0.69% at last look, the market valuation stands at $998.20M. ARDX’s current price is a ...Q1 net loss was $26.8 million, but Ardelyx raised $51.9 million through sales of their common stock at an average price of about $3.35, leaving $130.4 million in total cash and investments as of ...Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmission of a New Drug Application (NDA) for XPHOZAH® (tenapanor) for the control of serum phosphate in adult ...Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that...
ARDX Stock Overview ... Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal ...
ARDX Stock Overview ... Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal ...
Mar 3, 2023 · On March 3, 2023, Wedbush upgraded their outlook for Ardelyx (NASDAQ:ARDX) from Neutral to Outperform.. Analyst Price Forecast Suggests 47.30% Upside. As of March 4, 2023, the average one-year ... Ardelyx Inc (NASDAQ:ARDX) trade information. Ardelyx Inc (ARDX) registered a 3.20% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.20% in intraday trading to $4.51 this Thursday, 11/30/23, hitting a weekly high. The stock’s 5-day price performance is 4.64%, and it has moved by 14.18% in 30 days.The US FDA has accepted an NDA resubmission from Ardelyx ( NASDAQ: ARDX) for Xphozah (tenapanor) as a chronic kidney disease treatment. The agency determined the application is subject a a class 2 ...Free Trial NASDAQ:ARDX Ardelyx (ARDX) Earnings Date, Estimates & Call Transcripts $4.31 -0.01 (-0.23%) (As of 04:25 PM ET) Compare Today's Range $4.20 …Ardelyx, Inc.'s (NASDAQ:ARDX) top owners are individual investors with 53% stake, while20% is held by institutions. Read full article. Simply Wall St. November 8, 2022 at 5:48 AM ...Oct 31, 2023 · Shares of Ardelyx (NASDAQ: ARDX) were up 9.5% as of 3:47 p.m. after the biotech company announced better-than-expected third-quarter 2023 results. WALTHAM, Mass., Feb. 2, 2023 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that on January 27, 2023, the compensation committee of the company's …After Hours Volume: 64.24K. Close. Chg. Chg %. $4.3300. 0.3000. 7.44%. Ardelyx Inc. advanced stock charts by MarketWatch. View ARDX historial stock data and compare to other stocks and exchanges.Ardelyx, Inc. (NASDAQ:ARDX) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Ardelyx, Inc., a biopharmaceutical company, develops ...Ardelyx, Inc. Reports Employment Inducement Grants. WALTHAM, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on …
Webull offers ARDX Ent Holdg (ARDX) historical stock prices, in-depth market analysis, NASDAQ: ARDX real-time stock quote data, in-depth charts, free ARDX ...Dec 29, 2022 · Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biopharmaceutical company focused on the development of first-in-class remedies that meet significant unmet medical needs. Title. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result ...Ardelyx (NASDAQ:ARDX) shareholders have earned a 226% return over the last year. Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality ...Instagram:https://instagram. smgixweedstocksfree unusual options activity scannerwhat bank gives you a debit card right away WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...FREMONT, Calif. and WALTHAM, Mass., July 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that it has … dividend payment calculatoramerican gold standard Ardelyx, Inc. (NASDAQ:ARDX) is a Waltham, Massachusetts-based biotech company founded in 2007. The company has the distinction of developing and commercializing the first-in-class therapeutic for ... the complete foundation stock trading course Ardelyx, Inc. (NASDAQ:ARDX) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts.The analysts have sharply increased their revenue ...From discovery through commercialization, all of us at Ardelyx ® are driven to advance patient care with targeted, first-in-class, novel mechanism therapies that address significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to create targeted, first ...